Screening Clinical Trials for Prostate Cancer
Clinical trials are research studies that involve people. The clinical trials on this list are for prostate cancer screening. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Fluorine F 18 DCFPyL PET / CT in Detecting High-Grade Prostate Cancer in Participants with Elevated PSA
This phase II trial studies how well fluorine F 18 DCFPyL positron emission tomography / computed tomography (PET / CT) imaging works in detecting high-grade prostate cancer in participants with elevated prostate-specific antigen (PSA) levels. A PET scan uses radioactive material, also known as a radiotracer, injected into the blood to show the internal workings of the body. A CT scan uses x-rays and a computer to produce a 3-dimensional image of the body. Fluorine F 18 DCFPyL is a radioactive tracer, which when used with combined PET / CT imaging, may help doctors more accurately locate areas of high grade prostate cancer in participants with elevated PSA.
Location: Johns Hopkins University / Sidney Kimmel Cancer Center, Baltimore, Maryland
Shared Decision Making Intervention in Screening for Prostate Cancer in High-Risk African American Patients
This clinical trial studies shared decision making intervention in screening for prostate cancer in high-risk African American patients. Using decision aids such as culturally sensitive written material, verbal information, and videos to educate patients about screening may increase patient participation and increase confidence in participants' decisions. Raising awareness about prostate cancer in the communities may increase the patients’ willingness to be screened for prostate cancer once they have learned about it.
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET / CT in Newly Diagnosed Prostate Cancer
Background: Prostate cancer is a common cancer among men. There are several ways to treat it, including hormone blocking drugs, radiation therapy, and surgery. Researchers want to combine abiraterone and enzalutamide to see if there is a better way to treat prostate cancer. They also want to study a new radiotracer called 18F-DCFPyL, with the help of a scan called positron emission tomography / computed tomography (PET / CT) to see if there is a better way to detect prostate cancer. Objective: To develop improved techniques to localize and detect prostate cancer; and to develop new ways to treat prostate cancer Eligibility: Men ages 18 and older with prostate cancer that has not spread to other parts of the body Design: - Participants will have a medical evaluation to determine eligibility for the study. - Participants will take three different medications daily by mouth and receive two injections during the course of the study. - Participants will have a medical evaluation monthly (for 6 months) while taking the medications. - Participants will have prostate MRI and PET / CT scans before treatment, 2 months after starting treatment and again before surgery. The radiotracer will be given by injection about 2 hours before the whole-body scan. The PET / CT scan itself is about an hour. - Participants may be asked to do a biopsy before treatment and 2 months after starting treatment. - Participants will have a full medical evaluation before surgery to remove their prostate. - Participants will have a follow-up visit 3 months after surgery and then as needed. - Participants will be contacted once a year for their PSA and testosterone levels for 5 years...
Location: National Institutes of Health Clinical Center, Bethesda, Maryland